Have any questions? 706-721-6582 or cts@augusta.edu
- A RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FOR LARGE B-CELL LYMPHOMA (ALPHA3)
Clinical Trial
A RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FOR LARGE B-CELL LYMPHOMA (ALPHA3)
This study will evaluate the efficacy and safety of a new drug, ALLO-501A in patients with Large B-Cell Lymphoma who achieve MRD after 1st line therapy. The study is designed to see how well ALLO-501A treats your disease when given after a lymphodepletion regimen containing ALLO- 647 along with the chemotherapy agents fludarabine (F) and cyclophosphamide.
Eligibility Criteria
- Inclusion Criteria: 1. Male or female participants ? 18 years of age at the time of signing the informed consent 2. Have an ECOG performance status score of 0 or 1 3. Has Large B-cell lymphoma confirmed by pathology report and has completed a full course of standard 1st line therapy, including an anthracycline and an anti-CD20 monoclonal antibody. AND achieved CR or PR. Exclusion criteria: 1. Has CNS involvement or has arisen or transformed from other malignancy 2. Prior irradiation to >25% of bone marrow. 3. Prior treatment with anti-CD19 targeted therapies
RESEARCH. INNOVATION. DISCOVERY.